Logiscreen

Arcutis Biotherapeutics Inc

$21.23
Market Cap 2.63B
ROE -1.4%
Gross Margin 90.7%
Debt/Equity 0.6
Current Ratio 2.7
Revenue QoQ 60.1%
EPS QoQ -0.6%
F-Score 4

About

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including two FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-1145.85
vs median 31.50
P/B
14.36
vs median 2.17
ROE
-0.01
vs median 0.09

Lower quality - review fundamentals carefully

Mid-cap company with growth potential

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics